Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.44 EUR
Change Today +0.137 / 5.95%
Volume 103.5K
As of 3:59 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

biofrontera ag (B8F) Snapshot

Open
€2.31
Previous Close
€2.30
Day High
€2.55
Day Low
€2.31
52 Week High
05/8/14 - €3.30
52 Week Low
02/26/15 - €1.80
Market Cap
59.4M
Average Volume 10 Days
53.7K
EPS TTM
€-0.50
Shares Outstanding
24.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOFRONTERA AG (B8F)

Related News

No related news articles were found.

biofrontera ag (B8F) Related Businessweek News

No Related Businessweek News Found

biofrontera ag (B8F) Details

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; and Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

46 Employees
Last Reported Date: 04/10/15
Founded in 1997

biofrontera ag (B8F) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €405.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €202.0K
Compensation as of Fiscal Year 2014.

biofrontera ag (B8F) Key Developments

Biofrontera AG Establishes Subsidiary in US; Appoints Monica Tamborini as CEO of US Operations

Biofrontera AG has formed a wholly-owned US subsidiary, Biofrontera Inc., registered in Wilmington, Delaware. This company is intended to lay the ground for marketing and sales activities upon the expected FDA approval for the products Ameluz and BF-RhodoLED in 2016. Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica has over 20 years experience managing US companies in the healthcare sector. Monica worked in various sectors before joining the pharmaceutical industry. Since then, Monica has held various positions as CFO and COO. In addition to her expertise in finance Monica has, as Managing Director of Calix Consulting.

Biofrontera AG Announces Audited Consolidated Earnings Results for the Full Year Ended December 31, 2014; Provides Earnings Guidance for the Financial Year 2015

Biofrontera AG announced audited consolidated earnings results for the full year ended December 31, 2014. For the year, the company reported sales revenue of €3,095,555 against €3,114,551 a year ago. Loss from operations was €9,526,958 against €7,137,740 a year ago. Loss before income tax was €10,720,978 against €8,066,618 a year ago. Net loss for the year was €10,720,978 or €0.49 undiluted per share against €8,066,618 or €0.47 undiluted per share a year ago. Net cash flow into operations was €7,927,932 against €7,225,264 a year ago. Purchase of intangible and tangible assets was €164,082 against €341,980 a year ago. For the 2015 financial year, the company expects to achieve turnover of approximately €4 to €5 million, though this is still subject to significant planning uncertainties relating primarily to the speed of market penetration. The turnover forecast here does not include any additional licensing agreements with possible one-time payments. Moreover, the plans for 2015 do not take into consideration any down payment that may be made by a possible US sales partner, nor do they consider any additional costs that may be incurred if the company establishes its own sales division in the USA. The financial result reflects the interest payments and compounding of interest using the effective interest method for the two warrant bonds. Therefore, this will not significantly change in 2015 compared with 2014. The company will achieve a net loss of €9 to €10 million in 2015. The achievement of this result depends heavily on progress in terms of turnover.

Biofrontera AG, 2014 Earnings Call, Apr 10, 2015

Biofrontera AG, 2014 Earnings Call, Apr 10, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
B8F:GR €2.44 EUR +0.137

B8F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for B8F.
View Industry Companies
 

Industry Analysis

B8F

Industry Average

Valuation B8F Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOFRONTERA AG, please visit www.biofrontera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.